The present invention related to biotechnology and genetic engineering, particularly
the expression of proteins of viral origin in microorganisms through their fusion
by applying recombinant DNA technology to bacterial peptides. The present invention
provides an effcient process for the expression in Escherichia coli of heterlogous
proteins as fusion peptides with a view to obtaining them with a high degree of
purity, in commercially useful amounts, and in an appropriate form for their inclusion
in vaccine preparations. What is essentially used is a stabilizing sequence derived
from the first 47 amino acids of the antigen P64k of Neisseria meningitides
B:4:P1.15. In particular, use is made of a recombinant plasmid containing said
sequence, under the control of the tryptophane promoter of E. coli and of
the terminator of the transcription of the phage T4, including restrictions sites
which provide for the cloning in phase of DNA fragments coding for polypeptides
of interest.
